Danaher: Artificial Intelligence Is Revolutionising Laboratory Research
Danaher aims to significantly accelerate the development of new medicines and biotechnological processes. On October 7, the US group announced an AI-powered, largely autonomous research laboratory that is scheduled to begin operating in early 2027.
The facility is based at subsidiary Abcam’s site and combines artificial intelligence with robotics and technologies from other group brands. The aim is to make antibody and molecular tool development more efficient. According to the company, the time to discover suitable reagents is expected to fall to one-eighth of the previous duration. At the same time, production volumes are set to increase by a factor of 10. This is achieved through continuous data analysis, with each test result feeding directly into further model optimisation.
To expand automation in research, Danaher has also entered into a partnership with Nvidia. The agreement provides for the integration of Nvidia’s computing power and AI models into Danaher’s scientific instruments. Edge computing is intended to enable future processing of research data directly on the devices. The joint concept aims to run practical experiments to train the algorithms while the AI calculates improved testing procedures in parallel. Technical integration will begin with selected devices and later extend to other parts of the range.
Analysts at RBC Capital have raised their price target for Danaher shares from USD 215 to USD 250 and maintained their “Outperform” rating. The increase reflects higher valuations among comparable companies in the sector. UBS also sets a fair value of USD 250 and recommends buying the shares.
MustGrow Biologics: Bayer Partnership and Rising Demand
While major technology groups invest billions in research, MustGrow Biologics is working on a different kind of revolution. The Canadian company develops biological solutions based on mustard plants to reduce conventional agrochemical and fertiliser use while improving soil health. With the organic biofertility product, TerraSante™, MustGrow already has a commercially marketed product. The TerraMG™ crop protection technology opens up additional prospects in international markets.
The collaboration with Bayer for the pre-registered TerraMG™ is strategically important. In August, MustGrow reached its first major development milestone, which enabled licensing revenue of CAD 1.36 million in the first half of 2026. Bayer is working on the regulatory development of TerraMG™ for Europe, the Middle East and Africa (EMEA). Successful commercialisation could lead to further milestone payments, royalties and revenue from active ingredient production.
The operating business is also gaining momentum. By mid-August 2026, TerraSante™ had already generated revenue of around CAD 900,000. That is about a 46% increase over total sales in fiscal year 2025. Notably, limited production capacity, not demand, is currently holding back growth. At the International Investment Forum (IIF) on October 7, management confirmed that scaling up manufacturing is among its most important tasks.
Analysts at GBC see considerable potential. In their study published at the end of September, they reiterated their Buy recommendation and set a price target of CAD 2.51 (EUR 1.54) by the end of 2027. The experts expect revenue of CAD 14.05 million for 2027, rising to CAD 31.56 million for 2028. For EBITDA, analysts forecast a positive CAD 8.46 million for 2028. However, these estimates depend largely on successful production expansion.
A promising technology platform could become a scalable business model. The Bayer partnership provides additional credibility, while TerraSante™ already demonstrates that biological agricultural solutions can be marketed commercially.
Veralto: A Billion-Dollar Market for Clean Water
Clean water is becoming an increasingly valuable resource worldwide. The US group, headquartered in Waltham, Massachusetts, develops technologies for water analysis, disinfection and pollutant removal. Its portfolio includes the well-known brands Hach, Trojan Technologies and ChemTreat. It also offers solutions for quality assurance of industrial products and packaging.
In water treatment, the group is further expanding its business through a strategic acquisition announced back in August. The company is acquiring specialist Cleanwater1 for an effective purchase price of around USD 452 million. The acquisition brings Veralto additional expertise in water disinfection and solids treatment, as well as direct access to a base of around 25,000 already installed systems. The transaction, which is scheduled to close in the fourth quarter of 2026, is expected to have a neutral to slightly positive impact on adjusted earnings per share next year.
The company is also advancing its sustainability strategy. The independent organisation “Science Based Targets initiative” recently officially validated the company’s near-term climate targets. A key component is greater supply chain involvement. By 2030, 60% of suppliers are expected to have their own science-based emissions targets. In addition, Veralto plans to reduce greenhouse gas emissions generated by end customers’ use of its products by 61% relative to revenue by 2033. Direct and indirect emissions from its own operations are expected to fall by just under 55% over the same period. In this area, the company has already reported a 22% decline since 2023, largely driven by expanding renewable energy and electrifying its fleet.
Following the announcement, research firm Stifel reaffirmed its Buy recommendation for Veralto shares and maintained its fair value at USD 114. The analysts highlight the group’s strong gross margin of 60%, which provides a solid financial basis for such projects. In the second quarter, Veralto exceeded market expectations, posting adjusted earnings of USD 1.11 per share and revenue of USD 1.47 billion.
Conclusion
Danaher plans to accelerate biotechnology research with artificial intelligence. Veralto is focusing on the growing demand for clean water and expanding its market position through acquisitions. MustGrow Biologics holds enormous potential. The collaboration with Bayer, rising TerraSante™ sales, and planned production expansion could provide considerable tailwinds for the comparatively small company.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as “Relevant Persons”) may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a “Transaction”). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.